European Journal of Inorganic Chemistry, ISSN 1434-1948, 03/2012, Volume 2012, Issue 9, pp. 1469 - 1476
Reactions of [{Cp*IrCl(μ‐Cl)}2] (Cp* = η5‐pentamethylcyclopentadienyl) with bidentate pyridine–imine ligands such as 2‐(1‐hydrazonoethyl)pyridine (L1‐NH2) and...
Bimetallic complexes | Ruthenium | Iridium | Half‐metallocene complexes | N ligands | N ligands | Half-metallocene complexes | MOLECULAR-STRUCTURE | CHEMISTRY, INORGANIC & NUCLEAR | RHODIUM(III) COMPLEXES | CATIONIC IRIDIUM(III) COMPLEXES | BIFUNCTIONAL ASYMMETRIC CATALYSIS | ELECTRON-TRANSFER | GAS SHIFT REACTION | LIGANDS | SYSTEMS | N li-gands | DINUCLEAR COMPLEXES | METAL-COMPLEXES
Bimetallic complexes | Ruthenium | Iridium | Half‐metallocene complexes | N ligands | N ligands | Half-metallocene complexes | MOLECULAR-STRUCTURE | CHEMISTRY, INORGANIC & NUCLEAR | RHODIUM(III) COMPLEXES | CATIONIC IRIDIUM(III) COMPLEXES | BIFUNCTIONAL ASYMMETRIC CATALYSIS | ELECTRON-TRANSFER | GAS SHIFT REACTION | LIGANDS | SYSTEMS | N li-gands | DINUCLEAR COMPLEXES | METAL-COMPLEXES
Journal Article
Optics Letters, ISSN 0146-9592, 05/2018, Volume 43, Issue 10, pp. 2340 - 2343
A side-pump coupler made of fluoride fibers was fabricated and tested. The tested device had a coupling efficiency of 83% and was driven with an incident pump...
Journal Article
Optics Express, ISSN 1094-4087, 02/2018, Volume 26, Issue 3, pp. 3497 - 3507
Journal Article
OPTICS EXPRESS, ISSN 1094-4087, 02/2018, Volume 26, Issue 3, pp. 3497 - 3507
We have demonstrated the continuous-wave operation of a highly efficient 2.8 mu m Er-doped Lu2O3 ceramic laser at room temperature. An Er: Lu2O3 ceramic with a...
CONTINUOUS-WAVE | INTENSITIES | RARE-EARTH IONS | UP-CONVERSION | OPTICAL-PROPERTIES | FABRICATION | CRYSTAL | OPTICS | TRANSPARENT CERAMICS | ERZBLAN FIBER LASER | EFFICIENCY
CONTINUOUS-WAVE | INTENSITIES | RARE-EARTH IONS | UP-CONVERSION | OPTICAL-PROPERTIES | FABRICATION | CRYSTAL | OPTICS | TRANSPARENT CERAMICS | ERZBLAN FIBER LASER | EFFICIENCY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article